NCT06928818View on ClinicalTrials.gov

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions

Cancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Seoul National University Hospital

OTHER